公开(公告)号：WO2011057204A9

公开(公告)日：2011-09-09

申请号：PCT/US2010055857

申请日：2010-11-08

Applicant: UNIV JOHNS HOPKINS ,  LEE BYOUNG DAE ,  DAWSON TED M ,  DAWSON VALINA L ,  WEST ANDREW B

Inventor： LEE BYOUNG DAE ,  DAWSON TED M ,  DAWSON VALINA L ,  WEST ANDREW B

IPC: A61K31/403 ,  A61K31/404 ,  A61K31/416 ,  A61K31/519 ,  A61P25/00 ,  A61P25/28

CPC classification number: A61K31/553 ,  A61K31/122 ,  A61K31/403 ,  A61K31/404 ,  A61K31/416 ,  A61K31/519 ,  A61K31/7064

公开(公告)号：WO2007007985A2

公开(公告)日：2007-01-18

申请号：PCT/KR2006/002659

申请日：2006-07-07

Applicant: POSTECH FOUNDATION ,  POSTECH ACADEMY-INDUSTRY FOUNDATION ,  KIM, Youn-Dong ,  LEE, Byoung-Dae ,  KIM, Yoe-Kyung ,  BAE, Yoe-Sik ,  LEE, Tae-Hoon ,  SUH, Pann-Ghill ,  RYU, Sung-Ho

Inventor： KIM, Youn-Dong ,  LEE, Byoung-Dae ,  KIM, Yoe-Kyung ,  BAE, Yoe-Sik ,  LEE, Tae-Hoon ,  SUH, Pann-Ghill ,  RYU, Sung-Ho

IPC: A61K38/08 ,  A61K38/16

CPC classification number: A61K38/1796 ,  A61K38/08

Abstract: The present invention relates to a ligand to regulate immune response, i.e., PACAP27 which is one of pituitary adenylate cyclase-activating polypeptides and Serum amyloid A (SAA), and their novel use in treating or preventing diseases associated with immune response. More specifically, the present invention relates to a complex of PACAP27-FPRL1 having a regulatory effect on immune response, and a use thereof in regulating immune response. In another aspect, the present invention relates to a complex of SAA and FPRL1, and a use thereof in inhibiting synoviocyte hyperplasia and angiogenesis and treating or preventing inflammatory diseases including Rheumatoid arthritis (RA).

Abstract translation: 本发明涉及调节免疫应答的配体，即垂体腺苷酸环化酶活化多肽和血清淀粉样蛋白A（SAA）之一的PACAP27及其在治疗或预防与免疫应答有关的疾病中的新用途。 更具体地，本发明涉及具有对免疫应答的调节作用的PACAP27-FPRL1的复合物及其在调节免疫应答中的用途。 另一方面，本发明涉及SAA和FPRL1的复合物及其在抑制滑膜细胞增生和血管生成中的用途，并且治疗或预防包括类风湿性关节炎（RA）在内的炎性疾病。

公开(公告)号：WO2011057204A2

公开(公告)日：2011-05-12

申请号：PCT/US2010/055857

申请日：2010-11-08

Applicant: THE JOHNS HOPKINS UNIVERSITY ,  LEE, Byoung Dae ,  DAWSON, Ted M. ,  DAWSON, Valina L. ,  WEST, Andrew B.

Inventor： LEE, Byoung Dae ,  DAWSON, Ted M. ,  DAWSON, Valina L. ,  WEST, Andrew B.

IPC: A61K31/403 ,  A61K31/416 ,  A61K31/404 ,  A61K31/519 ,  A61P25/28 ,  A61P25/00

CPC classification number: A61K31/553 ,  A61K31/122 ,  A61K31/403 ,  A61K31/404 ,  A61K31/416 ,  A61K31/519 ,  A61K31/7064

Abstract: Leucine-rich repeat kinase-2 (LRRK2) mutations are a common cause of Parkinson's disease. Inhibitors of LRRK2 kinase that are protective in in vitro and in vivo models of LRRK2-induced neurodegeneration were identified. The presently disclosed subject matter establishes that LRRK2-induced degeneration of neurons in vivo is kinase dependent and that LRRK2 kinase inhibition provides a potential new neuroprotective paradigm for treating Parkinson's disease.

Abstract translation: 亮氨酸重复激酶-2（LRRK2）突变是帕金森病的常见病因。 鉴定了在LRRK2诱导的神经变性的体外和体内模型中保护的LRRK2激酶的抑制剂。 目前公开的主题确定LRRK2诱导的体内神经元的变性是激酶依赖性的，并且LRRK2激酶抑制提供了治疗帕金森病的潜在的新的神经保护范例。

公开(公告)号：WO2007007982A3

公开(公告)日：2007-01-18

申请号：PCT/KR2006/002656

申请日：2006-07-07

Applicant: POSTECH FOUNDATION ,  POSCO ,  YEA, Kyung-Moo ,  KIM, Jae-Yoon ,  KIM, Jong-Hyun ,  LEE, Byoung-Dae ,  LEE, Seung-Je ,  LEE, Tae-Hoon ,  SUH, Pann-Ghill ,  RYU, Sung-Ho

Inventor： YEA, Kyung-Moo ,  KIM, Jae-Yoon ,  KIM, Jong-Hyun ,  LEE, Byoung-Dae ,  LEE, Seung-Je ,  LEE, Tae-Hoon ,  SUH, Pann-Ghill ,  RYU, Sung-Ho

IPC: A61K31/7032 ,  A61K38/22 ,  A61P3/08

Abstract: The present invention relates to a glucose uptake modulator selected from the group consisting of a lysophosphatidyl derivative and urocortin, a pharmaceutical composition comprising the same, and a method of treating diabetes or diabetic complications in a mammal in need thereof.

公开(公告)号：WO2007007982A2

公开(公告)日：2007-01-18

申请号：PCT/KR2006002656

申请日：2006-07-07

Applicant: POSTECH FOUNDATION ,  POSCO ,  YEA KYUNG-MOO ,  KIM JAE-YOON ,  KIM JONG-HYUN ,  LEE BYOUNG-DAE ,  LEE SEUNG-JE ,  LEE TAE-HOON ,  SUH PANN-GHILL ,  RYU SUNG-HO

Inventor： YEA KYUNG-MOO ,  KIM JAE-YOON ,  KIM JONG-HYUN ,  LEE BYOUNG-DAE ,  LEE SEUNG-JE ,  LEE TAE-HOON ,  SUH PANN-GHILL ,  RYU SUNG-HO

IPC: A61K31/7032 ,  A61P3/08

CPC classification number: A61K31/7032 ,  A61K38/2228 ,  A61K38/28 ,  A61K2300/00

Abstract: The present invention relates to an glucose uptake modulator, a pharmaceutical composition comprising the glucose uptake modulator, and a method of treating a diabetes or diabetic complications in a mammal in need thereof, which comprises administering to said mammal an effecting amount of a glucose uptake modulator.

Abstract translation: 本发明涉及葡萄糖摄取调节剂，包含葡萄糖摄取调节剂的药物组合物和治疗有此需要的哺乳动物的糖尿病或糖尿病并发症的方法，其包括对所述哺乳动物施用有效量的葡萄糖摄取调节剂 。

公开(公告)号：WO2007007985A3

公开(公告)日：2007-04-05

申请号：PCT/KR2006002659

申请日：2006-07-07

Applicant: POSTECH FOUNDATION ,  POSTECH ACAD IND FOUND ,  KIM YOUN-DONG ,  LEE BYOUNG-DAE ,  KIM YOE-KYUNG ,  BAE YOE-SIK ,  LEE TAE-HOON ,  SUH PANN-GHILL ,  RYU SUNG-HO

Inventor： KIM YOUN-DONG ,  LEE BYOUNG-DAE ,  KIM YOE-KYUNG ,  BAE YOE-SIK ,  LEE TAE-HOON ,  SUH PANN-GHILL ,  RYU SUNG-HO

IPC: A61K38/08 ,  A61K38/16

CPC classification number: A61K38/1796 ,  A61K38/08

Abstract: The present invention relates to a ligand to regulate immune response, i.e., PACAP27 which is one of pituitary adenylate cyclase-activating polypeptides and Serum amyloid A (SAA), and their novel use in treating or preventing diseases associated with immune response. More specifically, the present invention relates to a complex of PACAP27-FPRL1 having a regulatory effect on immune response, and a use thereof in regulating immune response. In another aspect, the present invention relates to a complex of SAA and FPRL1, and a use thereof in inhibiting synoviocyte hyperplasia and angiogenesis and treating or preventing inflammatory diseases including Rheumatoid arthritis (RA).

Abstract translation: 本发明涉及调节免疫应答的配体，即作为垂体腺苷酸环化酶激活多肽和血清淀粉样蛋白A（SAA）之一的PACAP27，及其在治疗或预防与免疫应答相关的疾病中的新用途。 更具体地说，本发明涉及对免疫应答具有调节作用的PACAP27-FPRL1复合物及其在调节免疫应答中的用途。 另一方面，本发明涉及SAA和FPRL1的复合物及其在抑制滑膜细胞增生和血管生成以及治疗或预防包括类风湿性关节炎（RA）的炎性疾病中的用途。